Molecular Mechanisms and Therapeutics for SCA17

[1]  Yih-Ru Wu,et al.  Shaoyao Gancao Tang (SG-Tang), a formulated Chinese medicine, reduces aggregation and exerts neuroprotection in spinocerebellar ataxia type 17 (SCA17) cell and mouse models , 2019, Aging.

[2]  Shihua Li,et al.  The Expanding Clinical Universe of Polyglutamine Disease , 2019, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[3]  Yih-Ru Wu,et al.  The indole compound NC009–1 inhibits aggregation and promotes neurite outgrowth through enhancement of HSPB1 in SCA17 cells and ameliorates the behavioral deficits in SCA17 mice , 2018, Neurotoxicology.

[4]  S. Tabrizi,et al.  Effects of IONIS-HTTRx in Patients with Early Huntington’s Disease, Results of the First HTT-Lowering Drug Trial (CT.002) , 2018 .

[5]  G. Abbruzzese,et al.  Spinocerebellar ataxia 17: full phenotype in a 41 CAG/CAA repeats carrier , 2018, Cerebellum & Ataxias.

[6]  P. Jin,et al.  Piperine ameliorates SCA17 neuropathology by reducing ER stress , 2018, Molecular Neurodegeneration.

[7]  K. Maxwell,et al.  The Anti-CRISPR Story: A Battle for Survival. , 2017, Molecular cell.

[8]  B. Tang,et al.  Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17 , 2017, The Journal of Neuroscience.

[9]  Shihua Li,et al.  CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease , 2017, The Journal of clinical investigation.

[10]  C. Gomez,et al.  An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron , 2016, Science Translational Medicine.

[11]  G. Sobue,et al.  BIIB021, a synthetic Hsp90 inhibitor, induces mutant ataxin-1 degradation through the activation of heat shock factor 1 , 2016, Neuroscience.

[12]  H. Hsieh-Li,et al.  Targeting the prodromal stage of spinocerebellar ataxia type 17 mice: G-CSF in the prevention of motor deficits via upregulating chaperone and autophagy levels , 2016, Brain Research.

[13]  J. McBride,et al.  Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia. , 2016, Human molecular genetics.

[14]  Chung-Hsin Wu,et al.  Treatment with a Ginkgo biloba extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17 , 2016, Drug design, development and therapy.

[15]  C. Li,et al.  Piperine inhibit inflammation, alveolar bone loss and collagen fibers breakdown in a rat periodontitis model. , 2015, Journal of periodontal research.

[16]  Ji-feng Guo,et al.  Large Polyglutamine Repeats Cause Muscle Degeneration in SCA17 Mice. , 2015, Cell reports.

[17]  Guan-Chiun Lee,et al.  Trehalose Attenuates the Gait Ataxia and Gliosis of Spinocerebellar Ataxia Type 17 Mice , 2015, Neurochemical Research.

[18]  B. Davidson,et al.  Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  F. Pierelli,et al.  Psychiatric onset and late chorea in a patient with 41 CAG repeats in the TATA-binding protein gene. , 2014, Parkinsonism & related disorders.

[20]  Shuling Guo,et al.  Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. , 2014, Cell reports.

[21]  A. Spada,et al.  Muscle Expression of Mutant Androgen Receptor Accounts for Systemic and Motor Neuron Disease Phenotypes in Spinal and Bulbar Muscular Atrophy , 2014, Neuron.

[22]  Shihua Li,et al.  Age-Dependent Decrease in Chaperone Activity Impairs MANF Expression, Leading to Purkinje Cell Degeneration in Inducible SCA17 Mice , 2014, Neuron.

[23]  A. Lees,et al.  Late onset ataxia: MSA‐C or SCA 17? A gene penetrance dilemma , 2014, Movement disorders : official journal of the Movement Disorder Society.

[24]  N. Bonini,et al.  Hsp104 Suppresses Polyglutamine-Induced Degeneration Post Onset in a Drosophila MJD/SCA3 Model , 2013, PLoS genetics.

[25]  O. Riess,et al.  Automated home cage assessment shows behavioral changes in a transgenic mouse model of spinocerebellar ataxia type 17 , 2013, Behavioural Brain Research.

[26]  C. Calaminus,et al.  A Novel Transgenic Rat Model for Spinocerebellar Ataxia Type 17 Recapitulates Neuropathological Changes and Supplies In Vivo Imaging Biomarkers , 2013, The Journal of Neuroscience.

[27]  C. Hetz.  The unfolded protein response: controlling cell fate decisions under ER stress and beyond , 2012, Nature Reviews Molecular Cell Biology.

[28]  L. Lu,et al.  A Drosophila model of the neurodegenerative disease SCA17 reveals a role of RBP-J/Su(H) in modulating the pathological outcome. , 2011, Human molecular genetics.

[29]  Joseph J. Ling,et al.  Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor. , 2011, Brain : a journal of neurology.

[30]  H. Hsieh-Li,et al.  Neuroprotective effects of granulocyte‐colony stimulating factor in a novel transgenic mouse model of SCA17 , 2011, Journal of neurochemistry.

[31]  Shihua Li,et al.  Transcriptional dysregulation of TrkA associates with neurodegeneration in spinocerebellar ataxia type 17. , 2009, Human molecular genetics.

[32]  M. Saarma,et al.  Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Neurorestorative in Rat Model of Parkinson's Disease , 2009, The Journal of Neuroscience.

[33]  D. Hahm,et al.  Anti-inflammatory and antiarthritic effects of piperine in human interleukin 1β-stimulated fibroblast-like synoviocytes and in rat arthritis models , 2009, Arthritis research & therapy.

[34]  H. Paulson,et al.  In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis , 2009, Neurobiology of Disease.

[35]  Chuan-en Wang,et al.  Polyglutamine Expansion Reduces the Association of TATA-binding Protein with DNA and Induces DNA Binding-independent Neurotoxicity* , 2008, Journal of Biological Chemistry.

[36]  T. Ashizawa,et al.  Instability of expanded CAG/CAA repeats in spinocerebellar ataxia type 17 , 2008, European Journal of Human Genetics.

[37]  S. Warren,et al.  Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration , 2007, Nature Neuroscience.

[38]  H. Zoghbi,et al.  Trinucleotide repeat disorders. , 2007, Annual review of neuroscience.

[39]  Rodney C. Samaco,et al.  Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes , 2007, Nature Genetics.

[40]  J. Schwankhaus,et al.  Case of spinocerebellar ataxia type 17 (SCA17) associated with only 41 repeats of the TATA‐binding protein (TBP) gene , 2007, Movement disorders : official journal of the Movement Disorder Society.

[41]  Harry T Orr,et al.  Polyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzle. , 2006, Genes & development.

[42]  L. Goldfarb,et al.  Small de novo duplication in the repeat region of the TATA‐box‐binding protein gene manifest with a phenotype similar to variant Creutzfeldt‐Jakob disease , 2004, Clinical genetics.

[43]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[44]  Charles Duyckaerts,et al.  Behavioral disorder, dementia, ataxia, and rigidity in a large family with TATA box-binding protein mutation. , 2004, Archives of neurology.

[45]  G. Coppola,et al.  Intergenerational instability and marked anticipation in SCA-17 , 2003, Neurology.

[46]  Olaf Riess,et al.  Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17) , 2003, Annals of neurology.

[47]  I. Davidson.  The genetics of TBP and TBP-related factors. , 2003, Trends in biochemical sciences.

[48]  S. Viville,et al.  RNA Polymerase II Transcription in Murine Cells Lacking the TATA Binding Protein , 2002, Science.

[49]  Winship Herr,et al.  A Regulated Two-Step Mechanism of TBP Binding to DNA A Solvent-Exposed Surface of TBP Inhibits TATA Box Recognition , 2002, Cell.

[50]  C. Broeckhoven,et al.  CAG repeat expansion in the TATA box-binding protein gene causes autosomal dominant cerebellar ataxia. , 2001, Brain : a journal of neurology.

[51]  I. Kanazawa,et al.  SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. , 2001, Human molecular genetics.

[52]  S. Tsuji,et al.  Pathology of CAG repeat diseases , 2000, Neuropathology : official journal of the Japanese Society of Neuropathology.

[53]  S Kobayashi,et al.  A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? , 1999, Human molecular genetics.

[54]  Y. Matsuda,et al.  Analysis of the chicken TBP-like protein(tlp) gene: evidence for a striking conservation of vertebrate TLPs and for a close relationship between vertebrate tbp and tlp genes. , 1999, Nucleic acids research.

[55]  Harry T Orr,et al.  Ataxin-1 Nuclear Localization and Aggregation Role in Polyglutamine-Induced Disease in SCA1 Transgenic Mice , 1998, Cell.

[56]  Steven Finkbeiner,et al.  Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.

[57]  T. Crow,et al.  Analysis of polyglutamine-coding repeats in the TATA-binding protein in different human populations and in patients with schizophrenia and bipolar affective disorder. , 1996, American journal of medical genetics.

[58]  S. Burley,et al.  2.1 Å resolution refined structure of a TATA box-binding protein (TBP) , 1994, Nature Structural Biology.

[59]  N. Hernandez,et al.  TBP, a universal eukaryotic transcription factor? , 1993, Genes & development.

[60]  M. Horikoshi,et al.  Analysis of structure-function relationships of yeast TATA box binding factor TFIID , 1990, Cell.

[61]  Hitoshi Takahashi,et al.  Spinocerebellar Ataxia Type 17 (SCA17). , 2018, Advances in experimental medicine and biology.

[62]  B. Jeon,et al.  A patient with 41 CAG repeats in SCA17 presenting with parkinsonism and chorea. , 2016, Parkinsonism & related disorders.

[63]  H. Paulson,et al.  Silencing Mutant ATXN 3 Expression Resolves Molecular Phenotypes in SCA 3 Transgenic Mice , 2013 .

[64]  A. Gjedde,et al.  Huntington's disease-like and ataxia syndromes: identification of a family with a de novo SCA17/TBP mutation. , 2010, Parkinsonism & related disorders.

[65]  小出 玲爾,et al.  A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene : a new polyglutamine disease? , 2000 .

[66]  S K Burley,et al.  Biochemistry and structural biology of transcription factor IID (TFIID). , 1996, Annual review of biochemistry.